ClinicalTrials.gov
ClinicalTrials.gov Menu

Endometriosis Patients Undergoing Quinagolide Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00625950
Recruitment Status : Completed
First Posted : February 29, 2008
Last Update Posted : January 12, 2009
Sponsor:
Information provided by:
Instituto Valenciano de Infertilidad, IVI VALENCIA

Brief Summary:
Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Condition or disease Intervention/treatment Phase
Hyperprolactinemia Endometriosis Procedure: ENDOMETRIAL BIOPSY Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.
Study Start Date : February 2008
Actual Primary Completion Date : April 2008
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endometriosis


Intervention Details:
  • Procedure: ENDOMETRIAL BIOPSY
    Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.


Primary Outcome Measures :
  1. observation of three month treatment with Quinagolida in endometriosis patients [ Time Frame: onset and three months after onset ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 37 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hyperprolactinemia
  • Unexplained infertility
  • Endometriosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00625950


Locations
Spain
Instituto Valenciano de Infertilidad
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof. Dr. Antonio Pellicer, Instituto Valenciano de Infertilidad, Spain
ClinicalTrials.gov Identifier: NCT00625950     History of Changes
Other Study ID Numbers: VLC-AP-10208-208-1
First Posted: February 29, 2008    Key Record Dates
Last Update Posted: January 12, 2009
Last Verified: January 2009

Keywords provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:
Hyperprolactinemia
Endometriosis
laparoscopy
angiogenesis, VEGF

Additional relevant MeSH terms:
Endometriosis
Hyperprolactinemia
Genital Diseases, Female
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases